Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

FDA reins in Google-backed genetics company 23andMe

Health-related genetic test service put on hold pending US regulatory review
23andMe genetic testing kit

US-based 'personal genetics' company 23andMe has been forced to stop providing the public with health-related data until the service gets the all-clear from the FDA.

23andMe submitted its first application for FDA clearance in July 2012 and made another submission at the end of August but behind schedule with its responses, prompting a warning letter from the US regulator.

Responding to the FDA letter the Silicon Valley company said "we recognise that we have not met the FDA's expectations regarding timeline and communication regarding our submission".

Anne Wojcicki, co-founder and CEO of 23andMe, said: "We stand behind the data that we return to customers - but we recognise that the FDA needs to be convinced of the quality of our data as well.

"This is new territory for both 23andMe and the FDA. This makes the regulatory process with the FDA important because the work we are doing with the agency will help lay the groundwork for what other companies in this new industry do in the future. It will also provide important reassurance to the public that the process and science behind the service meet the rigorous standards required by those entrusted with the public's safety."

The Google-backed firm said its ancestry-related information and raw genetic data services would continue as before, but it's a major blow for the firm's mission to pioneer a new approach to genetic testing and research which will now have to wait for its tests to be approved by the FDA.

In the six years it has been running 23andMe has tested more 500,000 people and collected over 250 million survey data points, in the process building a crowd-sourced research database.

The company will continue to run its Parkinson's, sarcoma, MPN and African American research projects would continue, and plans to launch further research communities in 2014.

10th December 2013

From: Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics